Informace o publikaci
Health-economic challenges for new Alzheimer’s disease treatments
| Autoři | |
|---|---|
| Rok publikování | 2026 |
| Druh | Recenzovaný odborný článek |
| Časopis / Zdroj | JPAD-Journal of Prevention of Alzheimers Disease |
| Fakulta / Pracoviště MU | |
| Citace | |
| www | https://www.sciencedirect.com/science/article/pii/S2274580726000993 |
| Doi | https://doi.org/10.1016/j.tjpad.2026.100575 |
| Klíčová slova | Health economics; Alzheimer's disease; Cost-effectiveness modeling; Real-World Evidence |
| Přiložené soubory | |
| Popis | After decades of drug development setbacks, the Alzheimer’s disease (AD) research field is now experiencing major innovation across diagnostics and therapies. The first amyloid-targeting drugs for early-stage AD are available on the market in multiple countries. Yet these scientific breakthroughs have not translated into positive reimbursement decisions, as appraisal processes to date, including those in major health systems such as the United Kingdom (UK), France and Australia, have resulted in negative decisions. It is possible that these drugs will not become widely available in Europe. Many concerns hinder reimbursement, including the drug costs outweighing the benefits, uncertainty regarding both meaningfulness and long-term efficacy beyond trial follow-up periods, and safety considerations related to serious side effects. The 9th International Pharmaco-Economic Collaboration on Alzheimer’s Disease (IPECAD) meeting in Glasgow, Scotland in November 2025 brought together leading experts from academia, industry, regulatory bodies, and patient organizations to reflect on these challenges and chart future directions. We summarize the proceedings under three main topics. For details we refer to abstract and presentation slides on the IPECAD website www.ipecad.org. |
| Související projekty: |